PURPOSE: To introduce a new technique, involving the creation of a circumferential 360 degrees scleral relaxing incision, using an implant as large as 20 mm in diameter, and report on the surgical results in the treatment of severe phthisis bulbi, which are not indicated for classic evisceration. METHODS: The medical records of 20 patients with 20 phthisis bulbi who had undergone evisceration and placement, using the scleral capping technique, of porous polyethylene orbital implants as large as 20 mm in diameter between September 2002 and February 2006 were reviewed. For each patient, after evisceration, a circumferential 360 degrees equatorial scleral relaxing incision was made posterior to insertion of 4-recti muscles, and a porous polyethylene orbital implant was implanted. Each circumferential scleral relaxing incision wound was loosely sutured in the mattress fashion, using 5-0 braided polyester (Ethibond). RESULTS: The average of preoperative axial length, obtained using A scan and orbital computed tomography scan, was 16.8 mm. Orbital implants of 20 mm in diameter were implanted in all patients. The average of postoperative follow-up interval was 29.1 months. Orbital implant showed good motility to the satisfaction of all of patients. And the scleral capping technique could prevent complications, such as exposure of orbital implant, enophthalmos, and superior sulcus deformity. CONCLUSIONS: Scleral capping technique is safe and useful for evisceration in patients with severe phthisis bulbi. This technique can provide adequate space for the placement of and implant as large as 20 mm in diameter without generating any tension on wound. Consequently, this technique provided cosmesis and prosthesis motiliy, even without the use of a Medor coupling peg, with which patients were satisfied.
Congenital Abnormalities ; Enophthalmos ; Follow-Up Studies ; Humans ; Medical Records ; Muscles ; Orbit ; Orbital Implants ; Polyesters ; Polyethylene ; Prostheses and Implants ; Wounds and Injuries

PURPOSE: To report the case of a patient with large-angle hypertropia of an intramuscular hemangioma of the right superior rectus muscle (SR). METHODS: A 63-year-old man with progressive vertical deviation of the right eye for the past 6 months visited our strabismus department; his condition was not painful. An examination indicated that he had 60PD of right hypertropia at distance and near in primary gaze. Additionally, a significant limitation of his downgaze was noted. The right eye appeared mildly proptotic, and the upper and lower eyelids were slightly edematous. Corrected vision was 20/20 in both eyes. RESULTS: Orbital magnetic resonance imaging (MRI) studies revealed fusiform enlargement of the right superior rectus muscle, with prominent but irregular enhancement following gadolinium administration. Incisional biopsy revealed an intramuscular hemangioma in the superior rectus muscle with cavernous-type vessels. CONCLUSIONS: This case demonstrates that intramuscular hemangioma should be considered in the differential diagnosis of isolated extraocular muscle enlargement and unusual strabismus.
Strabismus/diagnosis/*etiology ; *Oculomotor Muscles ; Muscle Neoplasms/*complications/diagnosis ; Middle Aged ; Male ; Magnetic Resonance Imaging ; Humans ; Hemangioma/*complications/diagnosis ; Eye Neoplasms/*complications/diagnosis ; Disease Progression ; Diagnosis, Differential ; Biopsy

BACKGROUND AND OBJECTIVES: Glucose-insulin-potassium (GIK) fluid infusion may improve the myocardial energy metabolism in the ischemic condition. A prospective randomized clinical trial was designed to determine whether a GIK fluid infusion can reduce the ventricular remodeling in acute myocardial infarction. SUBJECTS AND METHODS: For the patients with acute myocardial infarction, during thrombolytic therapy with urokinase, GIK fluid (26% glucose 1000 mL, 50 IU insulin, and 80 mmol KCl) was administered for 24 hours. The ventricular volumes and function were evaluated by echocardiography during the admission period, at 6 months and at 12 months following discharge. RESULTS: This trial was done prospectively for 2 years in 73 patients; the GIK group included 41 patients and the control group included 32 patients. The median value of "the pain to door time" was 195 minutes in the GIK group and it was 120 minutes in the control group (p=NS). The wall motion score was 1.52+/-0.39 in the GIK group and it was 1.39+/-0.35 in the control group. The left ventricular volumes, ejection fractions, cardiac indices and the globular indices showed no significant difference between the two groups. The side effects of the GIK fluid were mild phlebitis in 6 patients (14.6%) and congestive heart failure in 5 patients (12.2%). CONCLUSION: This trial could not verify the beneficial effects of administering GIK fluid on the ventricular remodeling after acute myocardial infarction. The limitations of this trial were as follows: "the pain to door time" was too long and the severity of the myocardial infarction was mild. Low rates for the echocardiogrphy follow-up and the randomization failure in a few patients were also noted.
Echocardiography ; Energy Metabolism ; Follow-Up Studies ; Glucose ; Heart Failure ; Humans ; Insulin ; Myocardial Infarction* ; Phlebitis ; Prospective Studies ; Random Allocation ; Thrombolytic Therapy ; Urokinase-Type Plasminogen Activator ; Ventricular Remodeling